A group of 346 received a combined treatment consisting of chemotherapy and radiation over 21 weeks, a second group of 361 women received chemotherapy alone over 17 weeks.

Adjuvant chemotherapy for advanced endometrial cancer. For instance, doxorubicin can damage the heart muscle over time.

The targeted drug called trastuzumab (Herceptin®) might be added for carcinosarcomas that are HER2 positive. The American Cancer Society couldn’t do what we do without the support of our partners. Common side effects include: Also, most chemo drugs can damage the blood-producing cells of the bone marrow. The aim of the review: We aimed to determine whether chemotherapy after surgery is effective compared to radiotherapy, in women with advanced cancer of the womb. This evidence was of moderate quality. The standard of care for women with stage III/IVA endometrial cancer following surgery has been chemotherapy and radiation to prevent recurrence. Tax ID Number: 13-1788491. Women who received chemotherapy after surgery (starting within eight weeks of surgery) survived approximately 25% longer than those receiving radiotherapy after surgery. We wrote to the investigators of three trials for unpublished data. About 62,000 new cases will be diagnosed this year.

How was the review conducted? These include diarrhea, low blood counts, urinary symptoms and others. Endometrial Cancer Treatment (PDQ®)–Health Professional Version. Combination chemotherapy tends to work better than one drug alone. Occurrence of and mortality from endometrial cancer is rising, … It’s also important to follow recommended screening guidelines, which can help detect certain cancers early. Further research is needed to determine which chemotherapy regimen(s) are the most effective and least toxic, and whether the addition of radiotherapy further improves outcomes. Chemo is also commonly used for high grade cancers, which grow and spread quickly, and cancer that comes back after treatment. A median follow-up of six months after the randomized phase 3 trial showed the recurrence-free survival for the two arms of the trial were very similar: 59 percent for the group that got chemotherapy and radiation and 58 percent for chemotherapy alone. A large trial evaluating the benefits and risks of adjuvant chemoradiation versus chemotherapy in advanced endometrial cancer is ongoing. Two trials, evaluating 620 women (83% stage III, 17% stage IV), compared adjuvant chemotherapy with adjuvant radiotherapy; one trial evaluating 552 women (88% stage III, 12% stage IV) compared two chemotherapy regimens (cisplatin/doxorubicin/paclitaxel (CDP) versus cisplatin/doxorubicin (CD) treatment) in women who had all undergone adjuvant radiotherapy; and one trial contributed no data.